New Crown Pneumonia is a serious infectious disease that poses a great threat to human health and social stability. In order to fully combat the epidemic of New Crown Pneumonia, health insurance departments around the world have correspondingly introduced a series of reimbursement policies to promote better access to testing, treatment and other medical services for the majority of patients. Specifically, the cost of testing for C.pneumoniae can be included in the reimbursement scope of health insurance, and the related treatment cost and drug cost can also be supported by the corresponding reimbursement. In addition, in order to better protect the rights and interests of patients, many places have introduced additional medical assistance policies to provide poor patients with more support and assistance. Meanwhile, the reimbursement policy for outpatient special diseases has also been adjusted to provide greater support and assistance for epidemic prevention and control. Some regions have even extended the implementation period of the outpatient special disease reimbursement policy to facilitate more patients to enjoy the corresponding health insurance reimbursement policy.
How is the impact of the new Crown pneumonia outbreak on the health insurance fund? The New Crown Pneumonia outbreak has had a certain impact on the Medical Insurance Fund. On the one hand, the pressure and burden on medical institutions have been increased due to the concentration of people seeking medical care and treatment as a result of the outbreak; on the other hand, hospitals' expenditures on preventive and control materials, equipment, and training of personnel have increased significantly, all of which require the use of a larger sum of money. However, with the support of the state and the active regulation of medical insurance departments around the world, the overall operation of the medical insurance fund is still relatively stable, and no major risks and crises have occurred.
In response to the new coronary pneumonia epidemic, local health insurance departments have introduced corresponding reimbursement policies, including the costs of testing, treatment, and medicines for new coronary pneumonia, and have extended the implementation period of the reimbursement policy for outpatient special diseases. Although the epidemic has had a certain impact on the health insurance fund, there has not yet been a major risk or crisis.
Legal basis:
Article 12 of the Law of the People's Republic of China on the Prevention and Control of Infectious Diseases All units and individuals within the territory of the People's Republic of China must accept preventive and control measures such as investigations, tests, collection of samples, and isolation and treatment by disease prevention and control organizations and medical institutions concerning infectious diseases, and provide truthful information thereon. Disease prevention and control institutions, medical institutions shall not disclose relevant information and data involving personal privacy. Health administrative departments and other relevant departments, disease prevention and control institutions and medical institutions due to the illegal implementation of administrative or preventive, control measures, infringement of the legitimate rights and interests of units and individuals, the relevant units and individuals can apply for administrative reconsideration or litigation according to law.